Dr. Leanne Labriola is a board-certified ophthalmologist and serial entrepreneur, leading Visionaire as CEO. With a strong background in both academic and private healthcare, she specializes in uveitis and frequently performs anterior chamber paracentesis for diagnostics.

Leanne launched the clinical research program at Carle Foundation Hospital and has been the principal investigator for over 20 national clinical trials funded by the NIH, NSF, and private grants. With an MBA focused on Healthcare and Pharmaceutical Marketing, she brings extensive experience in clinical and translational research. Leanne also consults for major medical device companies and sits on advisory boards for new ophthalmology treatments. At Visionaire, she drives the technical development and commercialization of our groundbreaking diagnostics.

Rick brings over 40 years of experience in launching new technologies. He started as a Field Application Engineer in 1980 and rose to General Manager of a printed electronics division at Nissha, a global company with nearly $2 billion in sales across automotive, consumer electronics, and healthcare.

Rick’s expertise in business development for advanced materials and flexible electronics has already benefited our team. His extensive network of suppliers and manufacturers has been invaluable in commercializing multiple medical, analytical, and consumer electronics devices.

After a brief retirement in December 2020, Rick returned in March 2021 as Principal Investigator for a National Science Foundation grant on a novel ophthalmologic device, successfully meeting all milestones. He now leads the Phase II grant for further development of the device.

Kyla graduated Summa Cum Laude from Northeastern University in 2023 with a Bachelor’s in Bioengineering, focusing on medical devices and imaging. Her passion for medical diagnostics and optical imaging drove her to excel in both academics and hands-on research.

Kyla gained valuable experience during her co-ops, first at Selux Diagnostics as a Design Verification Engineer, where she worked on the Antibiotic Susceptibility Testing platform. She then joined Lyndra Therapeutics, honing her skills in manufacturing and optical imaging with the Process Analytical Technology team.

For her senior design project, Kyla developed a screening tool for toxic environmental exposure to volatile organic compounds (VOCs) using gas sensing technology. Now, she brings her expertise and enthusiasm for diagnostics to our team, pushing the boundaries of innovation in bioengineering.